New Real World Data (RWD) sources provide an unprecedented opportunity for Japanese companies to find, demonstrate and communicate their real value to patients, healthcare and society. 2018 is an important year, a turning point for Japan’s pharma industry, as the government and the industry encourage a rapid move towards increased use of Real World Evidence (RWE) from April 2018. As RWE moves from a niche topic into a strategic imperative demanded by the smartest senior executives, eyeforpharma’s in-depth conference has been redesigned to cover all of the key issues – and foster real progress in Japanese healthcare.
Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
